exercises for myopia
Article
How Much Of A Breakthrough Is Intralase In Lasik Eye Surgery
By John
Opting for the right LASIK surgery to correct your vision today is not the same as it was a decade ago. This is comparatively a recent medical breakthrough. It was only in 1994 that the first eye surgery was performed. Back then surgeons didn't have much option on how to go about the entire procedure. All they had was a microkeratome, a small mechanical blade which helped to create a flap on the cornea. Once the flap was created, conventional excimer laser was used for reshaping the tissue underneath.
That would allow the cornea to focus light directly on the retina exactly as it happens in a normal eye. This is all the option that an optometrist had about a decade ago. Since the this surgery has gone through a sea change and amazing advancements have been made in the technology that is being used. Lasers have become much smoother and precise which has allowed patients to have better vision than they could have ever imagined before.
One of the newest addition to this opertation technology is the machine called Intralase. This machine makes the metal blade redundant during a operation. Here flap creation is also done with the help of laser. So with the help of Intralase one can actually complete the entire surgery only using lasers. This makes the operation an all-laser surgery .
The greatest USP of Intralase is that it significantly reduces the risks of flap complications. When one is using the microkeratome to create the flap on the cornea there are risks of complications. These would include a flap being cut too thin, that the flap can tear, or may be it will not cut completely. Once you start using Intralase, such possibilities are almost done away with.
As the level of accuracy increases with the use of Intralase, the cases of re-operation also drop. That way it is a much safer option compared to microkeratome. But it must be understood that Intralase is not completely risk free. Flap related wrinkles and other similar problems are still a possibility eve with Intralase around. But it is also true that Intralase will bring down the actual cases of complications.
There are detractors to Intralase whose man line of argument would be that it is too new a method to jump to conclusions and that there is no substantial evidence that prior risks are negated. Also Intralase increases the length of an operation thereby increasing the opportunity for other complications to be introduced.
Article Source: http://www.article-outlet.com/
![]() |
Can You Not Read The Billboards Without Glasses?
By John Many of us suffer from the problem of being unable to read things at a distance. Medically such a condition would be termed as myopia. The only option till recently was to wear glasses. The worse Read more... |
![]() |
Latest Advances In Lasik Eye Surgery By John It was only towards the very end of the last decade that the excimer laser was approved by the FDA for lasik eye surgery. But within ten years there has been a whole host of companies which have Read more... |
Related RSS Feeds
Article Title: Promedior Announces Initiation Of Phase 2a Of Anti-Fibrotic Therapeutic, PRM-151, In The Prevention Of Post-Surgical Scarring In Glaucoma Patients Release Date: Thu, 09 Sep 2010 01:00:00 PDT Description: Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery... |
Article Title: Can-Fite BioPharma Announces The Initiation Of Phase 3 In Dry Eye Syndrome Release Date: Wed, 08 Sep 2010 07:00:00 PDT Description: Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome... |
Article Title: ThromboGenics Presents Positive Pooled Results From The MIVI-TRUST Phase III Program Release Date: Tue, 07 Sep 2010 00:00:00 PDT Description: ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France... |
Article Title: American Academy Of Ophthalmology Joins Forces With Middle East Africa Council Of Ophthalmology For Joint Meeting In Chicago October 16 To 19 Release Date: Mon, 06 Sep 2010 02:00:00 PDT Description: The largest and most comprehensive ophthalmic educational meeting in the world, the American Academy of Ophthalmology's (Academy) 2010 Joint Meeting in conjunction with the Middle East Africa Council of Ophthalmology (MEACO) will be taking place in Chicago, October 16 to 19... |


